TriSalus Life Sciences, Inc.
TriSalus Life Sciences is a U.S.-based medical device company focused on catheter-based infusion systems used in interventional oncology procedures. Its core product platform, TriNav, is designed for delivery in embolization workflows and is sold directly to hospitals, clinics, and physicians in the United States.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueCatheter-based infusion devices used in embolization procedures, primarily TriNav.
Infusion systems sold for interventional radiology and oncology procedures.
Customers
TriSalus sells directly to hospitals, clinics, and ambulatory surgery centers that perform embolization procedures, especially interventional radiology and oncology departments. The buying decision often involves physicians, interventional radiologists, medical oncologists, nursing staff, and value analysis committees that evaluate clinical utility and purchasing economics.
Buy TriNav for embolization procedures and evaluate it through clinical and procurement committees.
Use the device in TACE, TARE, and related procedures and influence adoption.
Support treatment planning for liver cancer patients and may recommend use.
Purchase devices for outpatient or clinic-based interventional procedures.
Review clinical and economic justification before hospital adoption.
Strategy
TriSalus’ strategy centers on expanding adoption of TriNav among interventional radiologists and hospital systems through direct clinical engagement and education. The company also emphasizes support services, including reimbursement and technical assistance, to reduce adoption friction and strengthen its position in procedure-based purchasing decisions.
Procedure volume and physician familiarity drive recurring device usage.
Hospital purchasing depends on clinical trust and committee approval.
Clinical and advocacy relationships can widen awareness and use cases.
Geography
TriSalus is headquartered in Westminster, Colorado and sells primarily in the United States through a direct sales force. The company’s commercial focus is nationwide, with emphasis on hospitals and major academic medical centers that perform higher volumes of embolization procedures.
Risks
TriSalus faces the risks typical of an early-stage medical device company, including customer concentration, limited contractual lock-in, and dependence on physician adoption. Its business is also exposed to regulatory, reimbursement, product liability, cybersecurity, and supply-chain risks, while ongoing losses and capital needs can constrain execution.
- Customer termination and weak contractual lock-inImpact: HighLikelihood: Medium
Many agreements are not long-term and some consignment deals can be ended with short notice.
Exposure: Hospital and clinic customers
- Dependence on physician adoptionImpact: HighLikelihood: Medium
Interventional radiologists and hospital committees influence whether TriNav is used.
Exposure: Procedure-based demand
- Regulatory and reimbursement riskImpact: HighLikelihood: Medium
Device use and hospital economics depend on healthcare regulation and payment support.
Exposure: U.S. hospital purchasing
- Financing and liquidity riskImpact: HighLikelihood: Medium
The company has not yet generated enough cash from operations to fund growth.
Exposure: Capital markets access
- Competitive and technological changeImpact: MediumLikelihood: Medium
The medical device market changes quickly and larger competitors may offer alternatives.
Exposure: Interventional oncology devices
- Supply-chain and cybersecurity disruptionImpact: MediumLikelihood: Medium
The company relies on third parties for manufacturing, systems, and clinical operations.
Exposure
Accounting
Judgemental itemsRevenue timing depends on when control transfers or devices are used in procedures.
Impact: Can shift revenue between periods
Contractual rebates are recorded as reductions of revenue when earned.
Impact: Reduces net sales and can affect quarterly comparability
These liabilities are remeasured and can create non-operating gains or losses.
Impact: Can materially affect reported net loss
Raw materials, labor, overhead, and depreciation drive cost of goods sold.
Impact: Affects gross margin and operating leverage
Similar listed companies
Publicly listed companies with a comparable business focus.
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Penumbra Inc
PEN · Surgical & Medical Instruments & Apparatus
Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body.
Edwards Lifesciences Corp
EW · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences designs and sells structural heart therapies used to treat advanced cardiovascular disease, with a portfolio centered on transcatheter and surgical valve technologies.
InfuSystem Holdings, Inc
INFU · Surgical & Medical Instruments & Apparatus
Stereotaxis, Inc.
STXS · Electromedical & Electrotherapeutic Apparatus
Stereotaxis designs and sells robotic magnetic navigation systems used in minimally invasive cardiac and endovascular procedures.
Globus Medical, Inc
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
Last updated: 24/09/2026